We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Argenta Announces Collaboration with PainCeptor
News

Argenta Announces Collaboration with PainCeptor

Argenta Announces Collaboration with PainCeptor
News

Argenta Announces Collaboration with PainCeptor

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Argenta Announces Collaboration with PainCeptor"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Argenta Discovery Ltd. has announced that it has entered into development collaboration with PainCeptor Pharma Corp.

Under the terms of the agreement, scientists from the two companies will exploit Argenta’s expertise in computer-aided drug design and medicinal chemistry to accelerate PainCeptor’s ASIC (acid-sensing ion channel) development programme for pain therapeutics, targeting these sensory mechanisms which are associated with a variety of pain-related conditions, including cancer and arthritis.
 
Commenting on the agreement, Dr Christopher Ashton, Argenta’s CEO, said, "We are delighted that PainCeptor has chosen to work with Argenta on this exciting programme."

"This is our first collaboration with the company and we believe their decision to work with Argenta is a tribute to the capabilities and expertise of our drug discovery team. We look forward to building a successful and long-term relationship with PainCeptor."
 
"We are pleased to be working with the Argenta team and believe their scientific expertise and experience will complement our own efforts and help us move our projects forward in the most expedient manner," added Dr. Francine Gervais, PainCeptor’s Senior Vice-President, Pharmaceutical Development.

Advertisement